novo nordisk investor presentation

English (USA)

English (UK)

English (Canada)

English (India)

Deutsch (Deutschland)

Deutsch (Österreich)

Deutsch (Schweiz)

Français (France)

Français (Suisse)

Nederlands (Nederland)

Nederlands (België)

• Top Capitalization
• United States
• North America
• Middle East
• Sector Research
• Earnings Calendar
• Equities Analysis
• Most popular
• NVIDIA CORPORATION
• AMD (ADVANCED MICRO DEVICES)
• TESLA, INC.
• NIPPON ACTIVE VALUE FUND PLC
• MICROSOFT CORPORATION
• Index Analysis
• Indexes News
• EURO STOXX 50
• Currency Cross Rate
• Currency Converter
• Forex Analysis
• Currencies News
• Precious metals
• Agriculture
• Industrial Metals
• Livestock and Cattle
• CRUDE OIL (WTI)
• CRUDE OIL (BRENT)

• Developed Nations
• Emerging Countries
• South America
• Analyst Reco.
• Capital Markets Transactions
• New Contracts
• Profit Warnings
• Appointments
• Press Releases
• Security Transactions
• Earnings reports
• New markets
• New products
• Corporate strategies
• Legal risks
• Share buybacks
• Mergers and acquisitions
• Call Transcripts
• Currency / Forex
• Commodities
• Cryptocurrencies
• Interest Rates
• Asset Management
• Climate and ESG
• Cybersecurity
• Geopolitics
• Central Banks
• Private Equity
• Business Leaders
• All our articles
• Most Read News
• All Analysis
• Satirical Cartoon
• Today's Editorial
• Crypto Recap
• Behind the numbers
• All our investments
• Asia, Pacific
• Virtual Portfolios
• USA Portfolio
• European Portfolio
• Asian Portfolio
• My previous session
• My most visited
• Multibaggers
• Momentum stocks
• Undervalued stocks
• Quality stocks
• Quality stocks at a reasonable price
• Europe's family businesses
• Circular economy
• Wind energy
• Semiconductors
• The Internet of Things
• Unusual volumes
• New Historical Highs
• New Historical Lows
• Top Fundamentals
• Sales growth
• Earnings Growth
• Profitability
• Rankings Valuation
• Enterprise value
• Top Consensus
• Analyst Opinion
• Target price
• Estimates Revisions
• Top ranking ESG
• Environment
• Visibility Ranking
• Stock Screener Home
• The future of mobility
• The food of tomorrow
• Oversold stocks
• Overbought stocks
• Close to resistance
• Close to support
• Accumulation Phases
• Most volatile stocks
• Top Investor Rating
• Top Trading Rating
• Top Dividends
• Low valuations
• All my stocks
• Stock Screener
• Stock Screener PRO
• Portfolio Creator
• Event Screener
• Dynamic Chart
• Economic Calendar
• Our subscriptions
• Our Stock Picks
• Thematic Investment Lists

Novo Nordisk A/S

Dk0062498333, pharmaceuticals.

• Novo Nordisk A/S : Open the Q1 2024 investor presentation

Novo Nordisk

• a focused healthcare company

Investor presentation

First three months of 2024

ABIGAIL CONIAH

Abigail lives with obesity

United Kingdom

Progress on Strategic Aspirations 2025 Commercial execution

Innovation and therapeutic focus Financials

Forward-looking statements

Novo Nordisk's reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the statutory Annual Report 2023 and Form 20-F, which both were filed with the SEC in January 2024 in continuation of the publication of the Annual Report 2023, this presentation, and written information released, or oral statements made, to the public in the future by or on behalf of Novo Nordisk, may contain forward-looking statements. Words such as 'believe', 'expect, 'may', 'will', 'plan', 'strategy', 'prospect', 'foresee', 'estimate', 'project', 'anticipate', 'can', 'intend', 'target' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance identify forward-looking statements. Examples of such forward-looking statements include, but are not limited to:

• Statements of targets, plans, objectives or goals for future operations, including those related to Novo Nordisk's products, product research, product development, product introductions and product approvals as well as cooperation in relation thereto,
• Statements containing projections of or targets for revenues, costs, income (or loss), earnings per share, capital expenditures, dividends, capital structure, net financials and other financial measures,
• Statements regarding future economic performance, future actions and outcome of contingencies such as legal proceedings, and
• Statements regarding the assumptions underlying or relating to such statements.

These statements are based on current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. Novo Nordisk cautions that a number of important factors, including those described in this presentation, could cause actual results to differ materially from those contemplated in any forward-looking statements.

Factors that may affect future results include, but are not limited to, global as well as local political and economic conditions, such as interest rate and currency exchange rate fluctuations, delay or failure of projects related to research and/or development, unplanned loss of patents, interruptions of supplies and production, including as a result of interruptions or delays affecting supply chains on which Novo Nordisk relies, shortages of supplies, including energy supplies, product recalls, unexpected contract breaches or terminations, government- mandated or market-driven price decreases for Novo

Nordisk's products, introduction of competing products, reliance on information technology including the risk of cybersecurity breaches, Novo Nordisk's ability to successfully market current and new

products, exposure to product liability and legal proceedings and investigations, changes in governmental laws and related interpretation thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing and marketing, perceived or actual failure to adhere to ethical marketing practices, investments in and divestitures of domestic and foreign companies, unexpected growth in costs and expenses, strikes and other labour market disputes, failure to recruit and retain the right employees, failure to maintain a culture of compliance, epidemics, pandemics or other public health crises, the effects of domestic or international crises, civil unrest, war or other conflict and factors related to the foregoing matters and other factors not specifically identified herein.

For an overview of some, but not all, of the risks that could adversely affect Novo Nordisk's results or the accuracy of forward-looking statements in the Annual Report 2023, reference is made to the overview of risk factors in 'Risk Management' of the Annual Report 2023.

Unless required by law, Novo Nordisk has no duty and undertakes no obligation to update or revise any forward-looking statement after the distribution of the Annual Report 2023, whether as a result of new information, future events, or otherwise.

Important drug information

Victoza ® and Ozempic ® are approved for the management of type 2 diabetes only

Saxenda ® and Wegovy ® are approved for the treatment of obesity only

Strategic Aspirations 2025 |Highlights first three months of 2024

1 MAT (Moving annual total) value market share CER: Constant exchange rates; CV: Cardiovascular

Note: The strategic aspirations are not a projection of Novo Nordisk's financial outlook or expected growth

Light blue indicates developments in Q1 2024

Sales growth of 24% driven by both operating units

Reported geographic sales split for first quarter of 2024

Reported therapy area sales and growth for first quarter of 2024

1 'Other diabetes' is included in Total

IO: International Operations; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiwan; RoW: Rest of World; NAO: North America Operations; CER: Constant exchange rates

Note: Unless otherwise specified, sales growth rates are at CER

Diabetes value market leadership reached 34%

Novo Nordisk global diabetes value market shares

30.5% 32.2% 34.0%

Diabetes value market leadership expansion

driven by the GLP-1 franchise

Diabetes care sales grew by 24% (CER) with global value

market share increase driven by market share gains in both IO and NAO.

• Global diabetes value market share increased by 1.8%-points to 34.0%
• Exceeded strategic aspiration for 2025 by achieving a global diabetes market value of more than 1/3
• Novo Nordisk continues to be the global market leader in the GLP-1 segment with a 55.3% value market share
• Estimated global GLP-1 share of total diabetes prescriptions is 6.2%

CER: Constant exchange rates; IO: International Operations; NAO: North America Operations

Note: Sales growth rates are at CER

Source: IQVIA MAT, Feb 2024 (Spot rate); Volume growth based on Moving Annual Total (MAT); Market values are based on the list prices

International Operations diabetes care sales growth is driven by GLP-1 performance

IO: International Operations; NN: Novo Nordisk; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiwan; RoW: Rest of World; CER: Constant exchange rates Note that the market share and patient numbers are based on countries with IQVIA coverage. GLP-1 class growth calculated as Dec'23-Feb'24 vs Dec'22-Feb'23 (Rolling 3-month average) Source: IQVIA MAT, Feb 2024 (Spot rate). Volume packs are converted into full-year patients based on WHO assumptions for average daily doses; Market values are based on the list prices

GLP-1 class continues to grow in the US

NBRx: New-to-brand prescriptions; TRx: Total prescriptions; NN: Novo Nordisk; Scripts: Prescriptions; US: United States; SU: standard units

Note: Class growth calculated based on SU volume for diabetes GLP-1 as Q1 2024 vs Q1 2023

Source: IQVIA Xponent Plantrak, NBRx/TRx data from week ending 29 March 2024. Each data point represents a rolling four-week average.

Gradual increase of supply reflected in US Obesity prescription development

1 Annual growth at CER. Each NBRx and TRx data points represents one week of data; 2 IQVIA weekly, 12 April 2024

CER: Constant exchange rates; TRx: Total Prescriptions; AOM: Anti-Obesity Medications (includes Wegovy ® , Saxenda ® , Zepbound ® , Qsymia ® and Contrave ® )

Note: Sales growth at constant exchange rates.

Rare disease sales decreased by 3%

Rare blood disorders

Rare disease sales decrease is driven by:

• 20% sales increase in North America Operations positively impacted by gross-to-net adjustments
• 18% sales decline in International Operations

Rare blood disorders sales decreased by 4%, driven by:

• Driven by NovoSeven ® and haemophilia A, partially countered by increased haemophilia B sales

Rare endocrine disorders sales increased by 1% driven by:

• Sales for Norditropin ® increased by 38% in NAO, impacted by gross-to-net adjustments, and decreased by 52% in IO
• Sogroya ® has now been launched in five countries

1 Total includes "Other Rare disease", which consists of primarily Vagifem ® and Activelle ® ; 2 Comprises NovoSeven ® , NovoEight ® , Esperoct ® , Refixia ® and NovoThirteen ® ; 3 Primarily Norditropin ® CER: Constant exchange rates; Haem. A: Haemophilia A; Haem. B: Haemophilia B; NAO: North America operations; IO: International operations

Note: NovoThirteen ® is not shown for Rare blood disorders breakdown, only for the total bar. Unless otherwise specified, sales growth is at constant exchange rates.

Attachments

• Original Link
• Original Document

Novo Nordisk A/S published this content on 02 May 2024 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 02 May 2024 11:51:36 UTC .

Latest news about Novo Nordisk A/S

Chart novo nordisk a/s.

Company Profile

Income statement evolution, analysis / opinion.

Novo Nordisk CEO: Demand for Wegovy outstrips supply

May 02, 2024 at 12:36 pm EDT

NOVO NORDISK : Q1 beat; guidance upgrade but sentiment nonetheless dampened by price reductions

Novo Nordisk doesn't disappoint

Ratings for Novo Nordisk A/S

Analysts' consensus, eps revisions, quarterly earnings - rate of surprise, sector other pharmaceuticals.

• Stock Market
• NOVO B Stock
• News Novo Nordisk A/S

• Today's news
• Reviews and deals
• Climate change
• 2024 election
• Fall allergies
• Health news
• Mental health
• Sexual health
• Family health
• So mini ways
• Unapologetically
• Buying guides

Entertainment

• How to Watch
• My Portfolio
• Latest News
• Stock Market
• Biden Economy
• EV Deep Dive
• Stocks: Most Actives
• Stocks: Gainers
• Stocks: Losers
• Trending Tickers
• World Indices
• US Treasury Bonds
• Top Mutual Funds
• Highest Open Interest
• Highest Implied Volatility
• Stock Comparison
• Advanced Charts
• Currency Converter
• Basic Materials
• Communication Services
• Consumer Cyclical
• Consumer Defensive
• Financial Services
• Industrials
• Real Estate
• Mutual Funds
• Credit Cards
• Balance Transfer Cards
• Cash-back Cards
• Rewards Cards
• Travel Cards
• Student Loans
• Personal Loans
• Car Insurance
• Morning Brief
• Market Domination
• Market Domination Overtime
• Asking for a Trend
• Opening Bid
• Stocks in Translation
• Lead This Way
• Good Buy or Goodbye?
• Fantasy football
• Pro Pick 'Em
• College Pick 'Em
• Fantasy baseball
• Fantasy hockey
• Fantasy basketball
• Download the app
• Daily fantasy
• Scores and schedules
• GameChannel
• World Baseball Classic
• Premier League
• CONCACAF League
• Champions League
• Motorsports
• Horse racing
• Newsletters

New on Yahoo

• Privacy Dashboard

Yahoo Finance

Highlights to be presented at novo nordisk’s capital markets day 2024.

Bagsværd, Denmark, 7 March 2024 – Novo Nordisk is today hosting a Capital Markets Day (CMD) where the company is providing a progress update on its Strategic Aspirations 2025.

The day will be centred around the Strategic Aspirations. During the day, senior management presentations will cover corporate strategy and purpose & sustainability (ESG), Research and early development, Product Supply as well research and development pipeline and performance within Diabetes care, Obesity care and Rare disease. In addition, Novo Nordisk’s approach to Cardiovascular & emerging therapy areas and financials are presented.

The CMD will include break-out sessions covering Region EMEA, Region China and Data science & Artificial intelligence.

Key highlights of the day are:

Focus on early-stage pipeline expansion by building on core research capabilities and new technology platforms. Phase 1 data for amycretin, a novel GLP-1 and amylin co-agonist, will also be presented

Update on scaling of manufacturing capacity and plans to increase patient reach

Continued growth potential for GLP-1-based semaglutide treatments within Diabetes care and presentation of data from the kidney outcomes trial FLOW

Update on commercial launches for Wegovy ® in the US and International Operations, an update of the obesity research and development pipeline, including additional data from the cardiovascular outcomes trial SELECT and overlap of comorbidities in people with cardiometabolic diseases

Update on the expanding pipeline within cardiovascular disease

Expected margin development in the coming years

All sessions of the CMD are webcast live, and a replay will be made available in the investor section of novonordisk.com. Presentation material from the CMD will also be available throughout the day in the investor section of novonordisk.com.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com , Facebook , Instagram , X , LinkedIn and YouTube .

Contacts for further information

PR240307-CMD

June 4, 2024

Novo Holdings appoints two new members to the Novo Advisory Group

Novo Holdings is pleased to announce the appointment of Joanne Burns and Philippe Houssiau to the Novo Advisory Group (NAG), an expert panel of senior industry leaders that supports Novo Holdings in analysing and monitoring its life science investments.

In addition to further strengthening the NAG, the appointments reinforce Novo Holdings’ focus on investing in the digital health/healthcare IT sector.

Kasim Kutay, CEO of Novo Holdings, said: “Joanne and Philippe both have extensive leadership experience from the Health Care and Life Sciences spectrum and strong expertise in healthcare IT. Their insights will be valuable to the NAG and we very much look forward to working with them.”

Philippe Houssiau fortifying healthcare IT leadership

Philippe Houssiau brings three decades of experience in healthcare, consulting and technology, and a strong international track record of executive leadership. As Partner and later Senior Partner with Price Waterhouse and PwC, he built and ran one of its consulting divisions globally and was a member of the Executive Committee.

After the sale of the PwC consultancy business to IBM, Philippe returned to the healthcare field. He consecutively held a variety of CEO and senior (non)-executive roles, in many cases in conjunction with  PE firms, including Agfa Healthcare, Alliance Medical, CSC/DxC, 4Ways Health, Hg Capital, Rhapsody, Mak System, Althea, and Mach7 Technologies.

Philippe currently holds five chair mandates with healthcare IT and Provider organisations in Europe and the US.

Philippe Houssiau said: “I am delighted to be joining the Novo Advisory Group. I look forward to getting the opportunity to draw on my expertise and contribute to Novo Holdings’ important mission of generating attractive financial returns on the assets of the Novo Nordisk Foundation.”

Joanne Burns adding strategic vision to shape healthcare innovation

Joanne Burns is a respected leader within the healthcare IT industry, with two decades of significant strategic, operational and governance experience at companies ranging from early-stage start-ups to Fortune 500 companies. Joanne is the former Chief Strategy Officer of Cerner Corporation, a role in which she was responsible for defining corporate strategy and plans with Cerner’s CEO while being known for her turnaround skills.

Before joining Cerner in 2004 as a Director in Product Development, Joanne held a position as Director of Information Technology at Stanford University Medical Center. Joanne has been acknowledged as a leader in the healthcare IT sector through her authorship, lectures, presentations, and awards, including Women to Watch in Health IT 2020, the American College of Healthcare Executives Fellowship, the HIMSS Fellowship, and Most Powerful Women in Health IT. Additionally, she has been a guest lecturer at the Wharton School and Purdue University.

Today, Joanne serves on the boards of Availity, ATI Physical Therapy, and SNOMED International.

Joanne Burns states: “I’m truly pleased to have the opportunity to join the Novo Advisory Group (NAG). My journey in healthcare IT has been driven by a passion for innovation and a commitment to improving patient outcomes. I look forward to leveraging my experience and expertise to help these organisations navigate the evolving landscape of healthcare technology while contributing to Novo Holdings’ mission and make a meaningful impact on people’s health and society.”

About Phillipe Houssiau and Joanne Burns

About Philippe Houssiau

Belgian citizen

Board positions

Philippe has extensive board experience and currently serves on the boards of medneo, RAM Infotechnology, and Corilus.

2022 – Executive Chairman, medneo

2021 – Non-Executive Director, RAM Infotechnology

2020 –  Chairman of the Board, Corilus

2021 – 2023 Non-Executive Director, Mach7 Technologies

2021 – 2022 Non-Executive Chairman, Althea

2020 – 2021 Interim Chief Executive Officer, MAK-SYSTEM

International Group

2019 – 2020 Chairman of the Board, Corepoint Health

2018 – 2020 Chairman of the Board, Rhapsody

2017 – 2020 Operating Partner, HgCapital

2015 – 2018 Chairman, 4ways

2013 – 2017 Vice President, General Manager Healthcare, DXC Technology

2010 – 2012 Group Chief Executive Officer, Alliance Medical Ltd

2009 – 2011 Chief Executive Officer, Telegentis NV

2002 – 2007 President, Healthcare Division, Agfa Gavaert Healthcare

1997 – 2002 Partner/Senior Partner, PwC

1994 – 1997 Director HR Europe, Raychem (now TE Connectivity)

Philippe holds a degree in Chemical Engineering/Biotech and a BSc in Pharmaceutical Sciences, both from Vrije Universiteit Brussel.

About Joanne Burns

Joanne is an experienced board professional and currently serves on the boards of ATI Physical Therapy, Availity, and SNOMED International.

2021 – Board of Directors, ATI Physical Therapy

2020 – Board of Directors, Availity

2007 – Chair Of the Board Of Directors, SNOMED

2019 – 2023 Board of Directors, Innara Health

2013 – 2019 Chief Strategy Officer, Cerner Corporation

2010 – 2013 CIO and VP, Executive Director, University of Missouri  Health Care, Tiger Institute for Health Innovation

2007 – 2010 Vice President, Product Development, Cerner Corporation

2004 – 2007 Director, Product Development, Cerner Corporation

1998 – 2003 Director of Information Technology, Stanford University Medical Center

1988 – 1998 Clinical Nurse, Stanford University Medical Center

Joanne holds a Registered Nursing Degree from the State University of New York at Plattsburgh, a Master’s degree in Health Services Administration from the University of San Francisco, and a ‘Women on Boards’ Program Certification from Harvard T.H. Chan School of Public Health.

About Novo Holdings A/S

Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seeds, Venture, Growth, Asia, Bioindustrial and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development.  As of year-end 2023, Novo Holdings had total assets of EUR 149 billion. www.novoholdings.dk

About the Novo Nordisk Foundation

Established in Denmark in 1924, the Novo Nordisk Foundation is an enterprise foundation with philanthropic objectives. The vision of the Foundation is to improve people’s health and the sustainability of society and the planet. The Foundation’s mission is to progress research and innovation in the prevention and treatment of cardiometabolic and infectious diseases as well as to advance knowledge and solutions to support a green transformation of society. www.novonordiskfonden.dk/en

Further information

Nils Eskestad, Senior Corporate Writer, [email protected]

q3-2022-presentation

1 Investor presentation First nine months of 2022 Morten Kruse Jacobsen (to the right), Senior Director at Novo Nordisk and married to Anders. Being a sustainable employer is a key priority for Novo Nordisk. This includes fostering a diverse and inclusive workplace. From January 2022, Novo Nordisk will offer a minimum of eight weeks paid parental leave to all non-birthing parents globally, regardless of gender.

Download PDF file

Senior Global Public Affairs Manager, Cities for Better Health

Job description

Bagsværd, Denmark

Job category

Corporate Affairs

Do you have both the passion for and a track record in strategically working with public health projects and public affairs? Are you motivated by improving the lives of people living with chronic diseases? Then you could be our new Senior Public Affairs Manager for Cities for Better Health. Apply today and join us for a life-changing career. 

The role  As our new Senior Public Affairs Manager, you will join the team responsible for global chronic disease policy in Novo Nordisk implementing the public affairs strategy for Novo Nordisk’s expanding portfolio in cardiovascular diseases and emerging therapy areas and securing a strategic collaboration with the Novo Nordisk initiative Cities for Better Health. 

Cities for Better Health is a global public-private partnership initiated by Novo Nordisk and committed to accelerating change in urban health across generations by building impactful local partnerships to drive health promotion and prevention. Our ambition is to address the root causes of chronic diseases in a holistic way by bringing together motivated actors across sectors and disciplines. For more information visit citiesforbetterhealth.com 

In the role as Senior Global Public Affairs Manager on Cities for Better Health, your key responsibilities will be:

• Strategically evaluate where to expand the program and identify opportunities for best practice sharing or expanded partnerships in key affiliates.
• Develop materials and resources to motivate affiliates to build local partnerships and drive awareness of the need for prevention efforts, with a focus on vulnerable populations in urban settings. 
• Support affiliates to strategically connect policymaker priorities with Novo Nordisk’s societal responsibility commitments and priorities. 
• Proactively assess and analyse trends and shifts in the political and public health environment to support the urban prevention agenda. 
• Work cross-functionally with project leads in Global Health Equity to ensure strong pipeline for affiliate projects and to amplify success stories internally and externally.

Qualifications  The preferred candidate holds a master’s degree in political science, international relations, or a related field. 

You are also expected to have the following:

• 5+ years’ experience working with Public Affairs in a public health context. 
• Ideally, you have experience working with an international initiative similar to Cities for Better Health. 
• Knowledge of how to navigate the complexities of many internal and external stakeholders. 

As a person you are  a strong team player with excellent interpersonal and stakeholder management skills, and ideally have experience working in a matrix organisation.  We expect you to have good communication and presentation skills as well as strong command of both written and spoken English. 

About the department and team  Global Public Affairs & Patient Relations (GPAPR) is part of the Global Public Affairs & Sustainability area in Novo Nordisk. We aspire to be a proactive and solutions-oriented partner to patients and policymakers in the joint ambition to raise the standards of care in our therapy areas and help solve society’s fundamental challenges. 

The role is anchored in Cardiovascular and Emerging Therapy Area Public Affairs Team that is driving the development and execution of the public affairs strategy for overarching chronic disease policy and Novo Nordisk’s expanding portfolio to cardiovascular disease, chronic kidney disease, liver diseases and Alzheimer’s disease.  The role will have close collaboration with the Novo Nordisk Health Equity Team leading the Cities for Better Health program.

Working at Novo Nordisk  At Novo Nordisk, we don’t wait for change. We drive it. We’re a dynamic company in an even more dynamic industry, and we know that what got us to where we are today is not necessarily what will make us successful in the future. We embrace the spirit of experimentation, striving for excellence without fixating on perfection. We never shy away from opportunities to develop, we seize them. From research and development, through to manufacturing, marketing and sales – we’re all working to move the needle on patient care. 

Contact   If you have questions about the position, you are welcome to contact Head of Chronic Disease Policy, Marie Louise Rostrup +4534481881 

Deadline  Please submit your application via our online application tool by 6th June 2024. 

We will screen applications continuously, so don’t hesitate to submit it as soon as possible. You do not need to attach a cover letter to your application, but please include a few sentences about why you are applying in your resume or CV. To ensure an efficient and fair recruitment process, please refrain from adding a photo in your CV.

We commit to an inclusive recruitment process and equality of opportunity for all our job applicants.    

We commit to an inclusive recruitment process and equality of opportunity for all our job applicants. 

At Novo Nordisk we recognize that it is no longer good enough to aspire to be the best company in the world. We need to aspire to be the best company for the world and we know that this is only possible with talented employees with diverse perspectives, backgrounds and cultures. We are therefore committed to creating an inclusive culture that celebrates the diversity of our employees, the patients we serve and communities we operate in. Together, we’re life changing.

Related jobs

Work with us

Patient Access, Public Affairs & Communication Director

Manila, Philippines

Public Affairs Manager

Lisbon, Portugal

Patient Education Manager

Nairobi, Kenya